Konttinen H., Cabral-da-Silva M.E.C., Ohtonen S., Wojciechowski S., Shakirzyanova A., Caligola S., Giugno R., Ishchenko Y., Hernandez D., Fazaludeen M.F., Eamen S., Budia M.G., Fagerlund I., Scoyni F., Korhonen P., Huber N., Haapasalo A., Hewitt A.W., Vickers J., Smith G.C., Oksanen M., Graff C., Kanninen K.M., Lehtonen S., Propson N., Schwartz M.P., Pebay A., Koistinaho J., Ooi L., Malm T. 2019. PSEN1DeltaE9, APPswe, and APOE4 confer disparate phenotypes in human iPSC-derived microglia. Stem. Cell Rep. 13, 669–683.

Article  CAS  Google Scholar 

Shelkovnikova T.A., Kulikova A.A., Tsvetkov F.O., Peters O., Bachurin S.O., Bukhman V.L., Ninkina.N. N. 2012. Proteinopathies, neurodegenerative disorders with protein aggregation-based pathology. Mol. Biol. (Moscow). 46, 362–374.

Article  CAS  Google Scholar 

Masters C.L., Bateman R., Blennow K., Rowe C.C., Sperling R.A., Cummings J.L. 2015. Alzheimer’s disease. Nat. Rev. Dis. Primers. 1, 15056.

Article  PubMed  Google Scholar 

Kozin S.A., Cheglakov I.B., Ovsepyan A.A., Telegin G.B., Tsvetkov P.O., Lisitsa A.V., Makarov A.A. 2013. Peripherally applied synthetic peptide isoAsp7-Abeta(1-42) triggers cerebral beta-amyloidosis. Neurotoxicity Res. 24, 370–376.

Article  CAS  Google Scholar 

Evin G., Li Q.X. 2012. Platelets and Alzheimer’s disease: potential of APP as a biomarker. W. J. Psychiatry. 2, 102–113.

Article  Google Scholar 

Vetrivel K.S., Thinakaran G. 2006. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology. 66, S69–73.

Article  CAS  PubMed  Google Scholar 

De Strooper B., Annaert W. 2010. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu. Rev. Cell. Dev. Biol. 26, 235–260.

Article  CAS  PubMed  Google Scholar 

Manczak M., Kandimalla R., Yin X., Reddy P.H. 2018. Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer’s disease. Hum. Mol. Genet. 27, 1332–1342.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan J.X., Sun D., Lee D., Xiong L., Ren X., Guo H.H., Yao L.L., Lu Y., Jung C., Xiong W.C. 2021. Osteoblastic Swedish mutant APP expedites brain deficits by inducing endoplasmic reticulum stress-driven senescence. Commun. Biol. 4, 1326.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tatarnikova O.G., Orlov M.A., Bobkova N.V. 2015. Beta-amyloid and tau protein: structure, interaction and prion-like properties. Usp. Biol. Khim. 55, 351–390.

Google Scholar 

Armstrong R.A. 2019. Risk factors for Alzheimer’s disease. Folia Neuropathol. 57, 87–105.

Article  Google Scholar 

Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13, 159–170.

Article  CAS  PubMed  Google Scholar 

Sasaguri H., Hashimoto S., Watamura N., Sato K., Takamura R., Nagata K., Tsubuki S., Ohshima T., Yoshiki A., Sato K., Kumita W., Sasaki E., Kitazume S., Nilsson P., Winblad B., Saito T., Iwata N., Saido T.C. 2022. Recent advances in the modeling of Alzheimer’s disease. Front. Neurosci. 16, 807473.

Article  PubMed  PubMed Central  Google Scholar 

Games D., Adams D., Alessandrini R., Barbour R., Borthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373, 523–527.

Article  CAS  PubMed  Google Scholar 

Kuo Y.M., Beach T.G., Sue L.I., Scott S., Layne K.J., Kokjohn T.A., Kalback W.M., Luehrs D.C., Vishnivetskaya T.A., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Weller R.O., Roher A.E. 2001. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol. Med. 7, 609–618.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274, 99–102.

Article  CAS  PubMed  Google Scholar 

Davis J., Xu F., Deane R., Romanov G., Previti M.L., Zeigler K., Zlokovic B.V., Van Nostrand W.E. 2004. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 279, 20296–20306.

Article  CAS  PubMed  Google Scholar 

Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. 2003. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39, 409–421.

Article  CAS  PubMed  Google Scholar 

Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. 2001. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Engin. 17, 157–165.

Article  CAS  Google Scholar 

Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. 2000. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050–4058.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. 2006. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940–946.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O’Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97–100.

Article  CAS  PubMed  Google Scholar 

Kurt M.A., Davies D.C., Kidd M., Duff K., Rolph S.C., Jennings K.H., Howlett D.R. 2001. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol. 171, 59–71.

Article  CAS  PubMed  Google Scholar 

McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., Yu X., Uljon S., Wang R., Mann D., Dickson D., Duff K. 1999. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis. 6, 231–244.

Article  CAS  PubMed  Google Scholar 

Toda T., Noda Y., Ito G., Maeda M., Shimizu T. 2011. Presenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer’s disease. J. Biomed. Biotechnol. 2011, 617974.

Article  PubMed  Google Scholar 

Rockenstein E., Mallory M., Mante M., Sisk A., Masliaha E. 2001. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J. Neurosci. Res. 66, 573–582.

Article  CAS  PubMed  Google Scholar 

Platt B., Drever B., Koss D., Stoppelkamp S., Jyoti A., Plano A., Utan A., Merrick G., Ryan D., Melis V., Wan H., Mingarelli M., Porcu E., Scrocchi L., Welch A., Riedel G. 2011. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One. 6, e27068.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saito T., Matsuba Y., Mihira N., Takano J., Nilsson P., Itohara S., Iwata N., Saido T.C. 2014. Single App knock-in mouse models of Alzheimer’s disease. Nat. Neurosci. 17, 661–663.

Article  CAS  PubMed  Google Scholar 

Sato K., Watamura N., Fujioka R., Mihira N., Sekiguchi M., Nagata K., Ohshima T., Saito T., Saido T.C., Sasaguri H. 2021. A third-generation mouse model of Alzheimer’s disease shows early and increased cored plaque pathology composed of wild-type human amyloid beta peptide. J. Biol. Chem. 297, 101004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jankowsky J.L., Xu G., Fromholt D., Gonzales V., Borchelt D.R. 2003. Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62, 1220–1227.

Article  CAS  PubMed  Google Scholar 

Lysikova E.A., Kukharsky M.S., Chaprov K.D., Vasilieva N.A., Roman A.Y., Ovchinnikov R.K., Deykin A.V., Ninkina N., Buchman V.L. 2019. Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes Brain Behav. 18, e12607.

Article  CAS  PubMed  Google Scholar 

D'Angelo C., Costantini E., Salvador N., Marchioni M., Di Nicola M., Greig N.H., Reale M. 2021. nAChRs gene expression and neuroinflammation in APPswe/PS1dE9 transgenic mouse. Sci. Rep. 11, 9711.